|
(2R,3R,4S,5R,6E)-3,4,5-Trihydroxy-N-[(3S,6R)-6-hydroxy-2-oxo-3-azepanyl]-2-methoxy-8,8-dimethyl-6-nonenamide
|
DB03396 |
|
|
Sanglifehrin A
|
DB03393 |
|
|
4-Deoxylactose
|
DB02065 |
|
|
Heptaethylene glycol
|
DB03394 |
|
|
Chromophore (Met-Tyr-Gly)
|
DB03391 |
|
|
(3,4,5-Trihydroxy-6-Hydroxymethyl-Tetrahydro-Pyran-2-Yl)-Phosphoramidic Acid Dimethyl Ester
|
DB03392 |
|
|
Cellobiose
|
DB02061 |
[A disaccharide consisting of two glucose units in beta (1-4) glycosidic linkage. Obtained from the partial hydrolysis of cellulose. [PubChem]] |
|
(2R,3R)-2,3-Dihydroxy-4-oxo-4-(propylamino)butanoic acid
|
DB03390 |
|
|
Cyclohexanone
|
DB02060 |
[Cyclohexanone (also known as oxocyclohexane, pimelic ketone, ketohexamethylene, cyclohexyl ketone or ketocyclohexane) is a six-carbon cyclic molecule with a ketone functional group. It is a colorless, oily liquid with an acetone-like smell.] |
|
Nitrate
|
DB14049 |
|
|
Cholesteryl chloride
|
DB14045 |
[Cholesteryl chloride, also known as 3-chlorocholest-5-ene, is an organochloride derivative of cholesterol. It is presented as a liquid crystal that forms clockwise liquid crystals.] |
|
ATB-346
|
DB15377 |
[ATB-346 is under investigation in clinical trial NCT03220633 (Study To Assess Safety, Tolerability And PK Of ATB-346 In Healthy Subjects).] |
|
Gosuranemab
|
DB15376 |
[Gosuranemab is under investigation in clinical trial NCT02460094 (Multiple Ascending Dose Study of Intravenously Administered BMS-986168 (BIIB092) in Patients With Progressive Supranuclear Palsy).] |
|
Dichlorobenzene
|
DB14046 |
[Dichlorobenzene refers to any of, or a mixture of, three isomers consisting of benzene in which two of the hydrogen atoms are replaced by chlorine atoms: ortho-, meta-, and paradichlorobenzene. It is a constituent of the ear-wax removal product Cerumol.] |
|
Hydroxypropyl betadex
|
DB15379 |
[Hydroxypropyl betadex is under investigation in clinical trial NCT03471143 (Study of IV VTS-270 for Infantile Liver Disease Associated With Niemann-Pick Disease, Type C).] |
|
Sodium zirconium cyclosilicate
|
DB14048 |
[Sodium zirconium cyclosilicate is approved as the trade product Lokelma developed by AstraZeneca - an insoluble, non-absorbed sodium zirconium silicate, formulated as a powder for oral suspension that acts as a highly selective potassium removing agent [L2933]. It is administered orally, is odorless, tasteless, and stable at room temperature [L2933]. It is a new medication that offers rapid and sustained treatment for adults with hyperkalaemia [L2933]. Approvals of the medication is supported by data from three double-blind, placebo controlled trials and two open-label trials which show that for patients receiving Lokelma the onset of action was at 1.0 hour and the median time to achieving normal potassium levels in the blood was 2.2 hours, with 92% of patients achieving normal potassium levels within 48 hours from baseline [L2933]. The treatment effect was maintained for up to 12 months [L2933].] |
|
Vopratelimab
|
DB15378 |
[Vopratelimab is under investigation in clinical trial NCT02904226 (JTX-2011 Alone and in Combination With Anti-PD-1 or Anti-CTLA-4 in Subjects With Advanced and/or Refractory Solid Tumors).] |
|
Fremanezumab
|
DB14041 |
[Fremanezumab is a genetically engineered humanized monoclonal antibody against human calcitonin gene-related peptide (CGRP) that is developed by Teva [A33105]. This therapy is given as a monthly subcutaneous injection and ongoing clinical trials for the agent are for episodic and chronic migraine as well as cluster headaches [A33114].] |
|
Tilmanocept
|
DB15373 |
[Tilmanocept is under investigation in clinical trial NCT03241446 (Pharmacokinetics and Dosimetry of Tc 99m Tilmanocept Following a Single Intravenous Dose Administration in Male and Female Subjects Diagnosed With Rheumatoid Arthritis (RA)).] |
|
JNJ-27548547
|
DB15372 |
[JNJ-27548547 is under investigation in clinical trial NCT01705002 (Intravenously Administered Pegylated Liposomal Mitomycin-C Lipid-based Prodrug (PROMITIL) in Cancer Patients With Solid Tumors.).] |
